Main takeaway: The company does not want to follow in the shoes of others by raising capital to fully purchase new assets. It is confident in its growth pipeline of diverse products.
AFT Pharmaceuticals is satisfied with its approach to innovation and product development and wouldn’t consider capital raising to outright purchase new intellectual property.
During AFT’s interim investor call, co-founder and chief executive Hartley Atkinson made reference to a Singaporean
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
Revenue: Up 27% to $84m.
Profit: Up 17% to $1.8m.
Main takeaway: The company does not want to follow in the shoes of others by raising capital to fully purchase new assets. It is confident in its growth pipeline of diverse products.
